Novel, even unlikely drugs may curb childhood leukemia

ul in other cancers as well."

Blocking cancer signals

News reports over the past year have heralded highly encouraging results from clinical trials of Glivec (STI-571) for adults with chronic myeloid leukemia (CML). Glivec represents a new class of drugs called signal transduction inhibitors that block the signaling pathways that cause cancer cells to grow. It is bioengineered to zero in on a cell receptor present in leukemia cells that carry a genetic defect called the Philadelphia chromosome.

This targeted approach causes minimal side effects to healthy tissue. While CML is rare in children, the same genetic defect found in CML, the Philadelphia chromosome, occurs in an aggressive form of childhood acute lymphoblastic leukemia (ALL).

Directed by Dr. Lange, Childrens Hospital is testing Glivec against that treatment-resistant form of ALL. Through its participation in the Childrens Oncology Group, a collaborative national organization that pools data and expertise from many cooperating cancer centers, Childrens Hospital is currently conducting pediatric trials of the drug. Because studies have suggested Glivec may have wider applications against other types of cancer, Childrens Hospital will test it later this year in children with highly malignant brain tumors.

Boosting immune effects

Also under the umbrella of the Childrens Oncology Group, Dr. Lange is leading tests of interleukin-2 (IL-2), a compound that occurs naturally in the body. IL-2 is an immune system protein that plays an important role in an immune response that occurs after a bone marrow transplant. In the "graft vs. leukemia effect," IL-2 stimulates the bodys natural killer cells to attack leukemia cells and drive the disease into remission.

The pediatric clinical trials led by Dr. Lange will test whether providing IL-2 can confer this benefit against acute myeloid leukemia (AML) in the absence of a marrow transplant. If so, said Dr. Lange, the approach may

Contact: John Ascenzi
Children's Hospital of Philadelphia

Page: 1 2 3 4

Related biology news :

1. Goals unlikely to protect Gulf of Mexico shrimp industry
2. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
3. Sex selection for social reasons unlikely to skew gender balance in Germany and UK
4. An unlikely new weapon against a deadly bacteria in oysters: A virus
5. Suppressing entire immune system unlikely to be best way to treat autoimmune diseases, new findings show
6. Depressed heart attack survivors unlikely to change behavior
7. New model of staph drug resistance implicates unlikely protein
8. One in three physicians unlikely to get routine medical care
9. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
10. New and better drugs for tuberculosis goal of UH professor
11. New technique helps scientists reveal interactions between genes and drugs

Post Your Comments:

(Date:12/14/2019)... ... December 11, 2019 , ... Fiberstar, Inc., a ... beverage industry won the 2019 Food Ingredient Europe’s plant-based innovation award. , This ... plant-based foods category. Fiberstar who was one of three finalists achieved this award ...
(Date:12/4/2019)... ROCHELLE, Va. (PRWEB) , ... December 04, 2019 ... ... announced today that Dr. Marque Todd , a regulatory toxicology expert with ... the firm as an Expert Consultant. , Dr. Todd has extensive experience ...
(Date:11/27/2019)... (PRWEB) , ... November 26, 2019 , ... ... patients to their Glen Ellyn, IL practice for Invisalign® treatment. Invisalign ... teeth. , Patients with a misaligned bite, also known as malocclusion, present both ...
Breaking Biology News(10 mins):
(Date:1/8/2020)... ... January 08, 2020 , ... RMA of ... and individuals grow their family, has announced that five of their Board-Certified reproductive ... Since 1991, the renowned publishing company Castle Connolly has compiled the ...
(Date:1/7/2020)... ... 06, 2020 , ... ABCT , the Accelerator for ... to participate in the annual program. Twelve ventures will participate in the 6.5-month-long ... network. All startups will receive an entrepreneur coach, access to active business professionals ...
(Date:12/27/2019)... ... December 27, 2019 , ... Vici ... 505(b)(2) product pipeline that offers patients and healthcare providers options in ... were identified in collaboration with doctors and managed care professionals and developed at ...
(Date:12/14/2019)... N.J. (PRWEB) , ... December 12, 2019 , ... ... manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical ... launch of 2019. The new LDA LT80 (LOW TEMPERATURE -80C) helium leak testing ...
Breaking Biology Technology:
Cached News: